Oracle, AbbVie And This Gold Fund: CNBC’s ‘Final Trades’
On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management named Oracle Corporation (NYSE: ORCL) as his pick.
Best-Selling Drugs by Bristol Myers, Pfizer, AbbVie Likely Candidates For US Price Negotiation
Bristol Myers Squibb & Co’s (NYSE:BMY) Eliquis, Pfizer Inc’s (NYSE:PFE) Ibrance, and AbbVie Inc’s (NYSE:ABBV) Imbruvica are expected to be among the ten…
Health Care ETFs Have Lost In The Last Month – These Top Pharma Stocks Are The Reason
The Health Care Select Sector SPDR Fund (NYSE:XLV), heavily tilted towards mega-caps, lost around 5.25% over the last month, with substantial companies…
8 Analysts Have This to Say About AbbVie
Over the past 3 months, 8 analysts have published their opinion on AbbVie (NYSE:ABBV) stock. These analysts are…
AbbVie Can Write Diversified Growth Story Without Humira, Rest Of The Business Has Strength, Analyst Says
Guggenheim initiated coverage on AbbVie Inc (NYSE:ABBV) with a Buy and a price target of $172 on diversified growth. Investors have “naturally” been…
Peering Into AbbVie’s Recent Short Interest
AbbVie's (NYSE:ABBV) short percent of float has risen 13.79% since its last report. The company recently reported that it has 11.71 million shares sold short, which is 0.66% of all regular shares that are available for trading.
Wall Street’s Most Accurate Analysts Say Hold These 3 Healthcare Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Wolfe Research Downgrades AbbVie to Peer Perform
Wolfe Research analyst Tim Anderson downgrades AbbVie (NYSE:ABBV) from Outperform to Peer Perform.
3 Stocks At An Inflection Point
With consumer and producer prices surprising to the upside, multiple research outlets are starting to call for more…
Where AbbVie Stands With Analysts
Within the last quarter, AbbVie (NYSE:ABBV) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish…